CPA
ELEV

Capital Performance Advisors’s Elevation Oncology ELEV Stock Holding History

Capital Performance Advisors’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11
Closed -$7 – 918
2024
Q3 		$7 Buy
+11
New +$16 ﹤0.01% 2887

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Performance Advisors's ELEV Position: Q4 2024 in Review

Capital Performance Advisors sold out of Elevation Oncology (ELEV) in Q4 2024, closing a stake of 11 shares — an estimated $7 sold.

Capital Performance Advisors first reported a position in ELEV in Q3 2024 and held it in 1 quarter. The position peaked at $7 in Q3 2024. 71 funds tracked by Wall St. Rank hold ELEV as of Q4 2024.

  • Capital Performance Advisors reported no remaining Elevation Oncology position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 11 Elevation Oncology shares in Q4 2024, an estimated $7.
  • Capital Performance Advisors first reported a position in Elevation Oncology in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Elevation Oncology position peaked at $7 in Q3 2024.
  • 71 funds tracked by Wall St. Rank held Elevation Oncology as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.